PharmX Technologies (PHX) investor relations material

Key strategic developments

• Multi-year strategic alliance with Sigma | Chemist Warehouse, including a 5-year EDI renewal and board representation, supports core business and international expansion.

• Ongoing transformation from fragmented systems to a unified, AI-native platform, enabling vertical integration and international growth.

• Four growth workstreams over the next 24 months: Gateway modernization, Marketplace expansion, supplier growth, and data & analytics scaling.

• Targeting $100m annualized GTV run rate for Marketplace within 12 months and international expansion into Ireland and the UK.

• Strategic partnerships and alliances are central to accelerating growth and expanding market reach.

Financial and operational highlights

• Market cap of $85.7m, share price at $0.13, and 659.5m shares on issue as of June 2026.

• Revenue growth at 10.9% CAGR, with FY25 revenue at $6.7m, up 9% PCP; cash at bank $3.2m as of December 2025.

• FY25 Gateway GTV reached $23bn (+18% PCP), with ~7,000 ANZ pharmacies connected and 150 direct supplier integrations.

• Marketplace platform achieved 1,350 registered pharmacies by March 2026, with 57% average monthly GTV growth in Q1 2026.

• EBITDA margin targeted for sustainable double-digit growth over the next three years.

Product and platform evolution

• Transitioned from a fee-based EDI gateway to a full-service platform integrating EDI, Marketplace, and Data & Analytics.

• Gateway 5 modernization program underway, supporting AI-native workflows and reducing supplier onboarding time.

• Marketplace offers 40,000+ SKUs, multi-cart checkout, embedded analytics, and is expanding supplier and wholesaler participation.

• Data & Analytics platform provides real-time insights, demand planning, and product catalogue services, with recurring DaaS revenue scaling.

• Supplier Portal enables self-service onboarding, supporting vertical and international expansion.